Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 16/20 | 0.65 |
| ▸ | FLT3 | P36888 | 11/20 | 0.65 |
| ▸ | KIT | P10721 | 11/20 | 0.65 |
| ▸ | AURKA | O14965 | 6/20 | 0.52 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.52 |
| ▸ | CDK19 | Q9BWU1 | 2/20 | 0.52 |
| ▸ | CSF1R | P07333 | 6/20 | 0.50 |
| ▸ | FLT4 | P35916 | 6/20 | 0.50 |
| ▸ | PLK4 | O00444 | 5/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.50 |
| ▸ | MET | P08581 | 5/20 | 0.50 |
| ▸ | RPS6KB1 | P23443 | 5/20 | 0.50 |
| ▸ | CSNK1D | P48730 | 5/20 | 0.50 |
| ▸ | STK3 | Q13188 | 5/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.50 |
| ▸ | MARK2 | Q7KZI7 | 5/20 | 0.50 |
| ▸ | LYN | P07948 | 5/20 | 0.50 |
| ▸ | FLT1 | P17948 | 5/20 | 0.50 |
| ▸ | CDK1 | P06493 | 4/20 | 0.50 |
| ▸ | PRKACA | P17612 | 4/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3955233 | 0.90 | KDR (0.58) | KDRFLT3KITAURKAAURKB | |
| SCHEMBL425755 | 0.85 | KDR (0.77) | KDRFLT3KITAURKAAURKB | |
| SCHEMBL3960218 | 0.84 | KDR (0.67) | KDRFLT3KITAURKAAURKB | |
| Hydrochloric Acid SCHEMBL3957794 | 0.83 | KDR (0.66) | KDRFLT3KITAURKAAURKB | |
| SCHEMBL5226811 | 0.82 | KDR (0.48) | KDRFLT3KITAURKAAURKB | |
| SCHEMBL3955903 | 0.80 | KDR (0.45) | KDRFLT3KITAURKAAURKB | |
| SCHEMBL3958645 | 0.80 | KDR (0.69) | KDRFLT3KITAURKAAURKB | |
| SCHEMBL423362 | 0.79 | KDR (1.00) | KDRFLT3KITAURKAAURKB | |
| Hydrochloric Acid SCHEMBL3957832 | 0.78 | KDR (0.49) | KDRFLT3KITAURKAAURKB | |
| SCHEMBL422816 | 0.76 | KDR (0.79) | KDRFLT3KITAURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517902-B2 | Substituted indazoles, compositions containing the same, and the preparation and use thereof | AVENTIS PHARMA S.A. (FR) | 2009-04-14 | — | — | US | claimed |
| US-20070161626-A1 | Substituted Indazoles, Compositions Containing The Same, And The Preparation And Use Thereof | AVENTIS PHARMA S.A. (FR) | 2007-07-12 | — | — | US | claimed |
| CN-1980918-A | Substituted indazoles, compositions containing them, preparation and use | AVENTIS PHARMA SA (FR) | 2007-06-13 | — | — | CN | claimed |
| EP-1765813-A1 | SUBSTITUTED INDAZOLES, COMPOSITIONS CONTAINING SAME, PREPARATION AND USE | Aventis Pharma S.A. (FR) | 2007-03-28 | — | — | EP | claimed |
| WO-2006003276-A1 | SUBSTITUTED INDAZOLES, COMPOSITIONS CONTAINING SAME, PREPARATION AND USE | AVENTIS PHARMA S.A. (FR) | 2006-01-12 | — | — | WO | claimed |
| US-7517902-B2 | Substituted indazoles, compositions containing the same, and the preparation and use thereof | AVENTIS PHARMA S.A. (FR) | 2009-04-14 | — | — | US | disclosed |
| US-7517902-B2 | Substituted indazoles, compositions containing the same, and the preparation and use thereof | AVENTIS PHARMA S.A. (FR) | 2009-04-14 | — | — | US | disclosed |
| US-7517902-B2 | Substituted indazoles, compositions containing the same, and the preparation and use thereof | AVENTIS PHARMA S.A. (FR) | 2009-04-14 | — | — | US | disclosed |
| US-20070161626-A1 | Substituted Indazoles, Compositions Containing The Same, And The Preparation And Use Thereof | AVENTIS PHARMA S.A. (FR) | 2007-07-12 | — | — | US | disclosed |
| US-20070161626-A1 | Substituted Indazoles, Compositions Containing The Same, And The Preparation And Use Thereof | AVENTIS PHARMA S.A. (FR) | 2007-07-12 | — | — | US | disclosed |
| US-20070161626-A1 | Substituted Indazoles, Compositions Containing The Same, And The Preparation And Use Thereof | AVENTIS PHARMA S.A. (FR) | 2007-07-12 | — | — | US | disclosed |
| CN-1980918-A | Substituted indazoles, compositions containing them, preparation and use | AVENTIS PHARMA SA (FR) | 2007-06-13 | — | — | CN | disclosed |
| EP-1765813-A1 | SUBSTITUTED INDAZOLES, COMPOSITIONS CONTAINING SAME, PREPARATION AND USE | Aventis Pharma S.A. (FR) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006003276-A1 | SUBSTITUTED INDAZOLES, COMPOSITIONS CONTAINING SAME, PREPARATION AND USE | AVENTIS PHARMA S.A. (FR) | 2006-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161626-A1 | Substituted Indazoles, Compositions Containing The Same, And The Preparation And Use Thereof | CYP3A43, CYP3A7, CYP3A5 | KDR 4627/4885FLT3 310/4885KIT 870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.